darleukin

Darleukin is a fully human immunocytokine, created by fusing the human monoclonal antibody L19 to the cytokine interleukin 2 (IL-2). The L19 antibody specifically targets the EDB domain of fibronectin, which is abundantly expressed in tumor vasculature but not in most normal adult tissues. This design allows for selective delivery of IL-2 to tumor sites, enhancing local immune activation while minimizing systemic toxicity. Mechanistically, darleukin activates tumor-specific T cells and natural killer (NK) cells at the disease site, promoting anti-tumor immune responses. It has demonstrated strong anti-cancer activity both as monotherapy and in combination with other treatments such as stereotactic ablative radiotherapy (SABR) and anti-PD1 therapy. Darleukin is under clinical development primarily for non-small cell lung cancer and melanoma, with additional studies in other solid tumors[1][5][7].

Brand names

Fibromun

Other names

Darleukin (L19IL2)Darleukin/fibromun